Overview

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK of a single dose of KBP-5074 in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
KBP Biosciences
Collaborator:
Covance
Treatments:
Itraconazole
Rifampin